Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Claire Fabre, MD, PhD, Naoya Mimura, MD, PhD, Kathryn Bobb, MS, Gullu Gorgun, PhD, Diana D. Cirstea, MD, Yiguo Hu, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2902.

https://doi.org/10.1182/blood.V118.21.2902.2902

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Noopur S. Raje, MD, Naoya Mimura, MD, PhD, James E. Bradner, MD, Diana Cirstea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Michael Sellitto, Yiguo Hu, PhD, Claire Fabre, MD, PhD, Hiroto Ohguchi, MD, PhD, Jiro Minami, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 128.

https://doi.org/10.1182/blood.V118.21.128.128

Published: 2011

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Naoya Mimura, MD, PhD, Diana Cirstea, M.D., Loredana Santo, MD, Yiguo Hu, MD, PhD, Claire Fabre, MD, Noopur Raje, MD, Nikhil C. Munshi, MD, Paul G Richardson, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 2996.

https://doi.org/10.1182/blood.V116.21.2996.2996

Published: 2010

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

Journal Articles

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

Blood (2007) 110 (11): 1849.

https://doi.org/10.1182/blood.V110.11.1849.1849

Published: 2007

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 856.

https://doi.org/10.1182/blood.V108.11.856.856

Published: 2006

Journal Articles

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 2649.

https://doi.org/10.1182/blood.V108.11.2649.2649

Published: 2006

Journal Articles

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Claire Fabre, MD, Fatsiha Chermat, Laurence Legros, MD, Sophie Park, MD, François Dreyfus, MD, Françoise Isnard, MD, Florence Nowak, MD, Anne Marfaing, MD, Stéphane de Botton, MD, Marie-Pierre Noel, MD, Christophe Fruchart, MD, Thomas Prebet, MD, Norbert Vey, MD, Caroline Dartigeas, MD, Pierre Fenaux, MD PhD

Blood (2006) 108 (11): 2664.

https://doi.org/10.1182/blood.V108.11.2664.2664

Published: 2006

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Transplantation in Relapsed/Primary Refractory Follicular Lymphoma.

Claire Fabre, MD, Christian Recher, MD, Anne Huynh, MD, Françoise Rigal-Huguet, MD, Michel Abbal, MD, Nicole Dastugue, MD, Talal Al Saati, MD, Pierre Brousset, MD, Michel Attal, MD

Blood (2004) 104 (11): 2309.

https://doi.org/10.1182/blood.V104.11.2309.2309

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Non-Myeloablative Allogeneic Hematopoietic Transplantation in Relapsed/Primary Refractory Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only